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Electrical therapies by defibrillators (ICD) and resynchronization devices
(CRT-D – CRT-P), have demonstrated their benefits on symptoms, morbidity
and mortality in selected heart failure patients (HF). The ITHAQUE survey
aims to describe the different supports of patients in HF patients with impaired
left ventricular (LV) function (LV ejection fraction < 45%)
 
Methods:
 
 927 patients treated for HF were seen in outpatient visit with a
general cardiologist (75%) or in a tertiary center (25%). A survey of treat-
ments and follow-ups was completed by the physician. 3 groups under optimal
treatment, defined by the French Society of Cardiology (SFC) guidelines, have
been analyzed:
 
Gr1 – 
 
Class 1B (patients with ischemic cardiomyopathy and coronary
revascularization, NYHA II and III, LVEF <30%) – Class 2aB (30% 
 
Gr2 – 
 
Class 2aB (dilated cardiomyopathy, NYHA II and III, LVEF <30%)
and class 2bC (30% 
 
Gr3 – 
 
Class 1B (HF Patients, NYHA III and IV, LVEF <35% and QRS>
120 ms) 
 
Results:
 
 Of the total patients, 79 received an ICD (8.5%), 22 a CRT-D
(2.4%) and 76 a CRT-P (8.2%). On the other side, 279 patients eligible accor-
ding to the recommendations of the SFC did not receive additional treatment
with ICD or CRT (30%). Pharmacological treatment associated is mainly com-
posed of IEC (76.5%), Beta-blockers (76.6%), Diuretics (90%), anticoagulants
(80%) and Anti-arrhythmic (31%). 
Rules lifestyle modifications (77.8%) and practice of physical activity (31.2%)
are also prescribed, associated or not. 
 
Conclusion:
 
 Although the specific conditions of therapeutic patient must
be taken into account, the ITHAQUE survey did show that the electrical the-
rapies recommended by the SFC for heart failure patients with systolic dys-
function are underused. 
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Background:
 
 Chronic obstructive pulmonary disease (COPD) is an inde-
pendent risk factor for cardiovascular disease (CVD) including heart failure
(HF) and coronary arteries diseases, which are one of the leading causes of
morbidity and mortality in COPD patients. Thus, COPD could deteriorate HF
and explain the worst prognostic of the association of the two diseases.
Actually, there is no information about the real prevalence of COPD assessed
by systematic pulmonary function test in HF patients.
 
Purpose:
 
 Describe the prevalence of COPD in a systolic HF population.
 
Methods:
 
 COPD was systematically researched by pulmonary function test
in 274 patients (216 men) followed for systolic HF in the University’s Hospital
of Rangueil, Toulouse, France between April 2002 and April 2009. Degrees of
COPD were defined according to the GOLD classification.
 
Results:
 
 In the 274 systolic HF patients mean age was 61±11 years and
mean ejection fraction (EF) was 32±15 % with 130 (47 %) patients with
ischemic systolic HF. There was 112 (41 %) of COPD with 57 (20.8 %), 44
(16.1 %), 7 (2.6 %) and 4 (1.5 %) GOLD 1, 2, 3 and 4 respectively. There was
not difference between no-COPD and COPD groups in sex (77.7 vs 75.9 %
men; p=0.1) and NYHA stage (mean 2.2±0.7 vs 2.3±0.8; p=0.3) but patients
with COPD were older (66.1±11 vs 57.1±13.7 years; p<0.001) and had better
EF (33.5±9.4 vs 30.2±12.9 %; p=0.016). There was 43.8 % ischemic heart
failure in the COPD group versus 51.8 % in the no-COPD group (p=0.13) and
no-COPD group had a tendency to have more ß-blocker treatment (74.1 vs
62.5 %; p=0.051).
 
Conclusion:
 
 COPD has a high prevalence in systolic HF population but
clinical diagnostic is difficult because of the lack of specificity of dyspnoea
assessed by NYHA stage. HF patients with COPD are older and have a better
EF suggesting that dyspnoea from pulmonary disease is interpreted as a
symptom of HF.
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Background:
 
 We describe the baseline characteristics of subjects prospec-
tively recruited in the KaRen morbidity-mortality French and Swedish
registry. KaRen’s purpose is to study the impact of dyssynchrony (electrical
and/or mechanical) on the prognosis of heart failure patients with preserved
ejection fraction. 
 
Methods and results:
 
 the Karen study is an ongoing study with a minimum
follow-up of 18-month for every patient. Here, we are reporting the initial cha-
racteristics of the 268 first patients included in the registry. These heart failure
patients with preserved ejection fraction recruited in university hospitals are
old.The mean age is 76.5 years old. 43% are between 80 and 89 years old.
59% were women. 10% of them have a bundle branch block. The prevalence
of hypertension is 75%, coronary artery disease 31%, valvular heart disease
20%, atrial fibrillation 88%, pulmonary primitive disease 24%, peripheral vas-
cular disease 15%, renal insufficiency 26% (creatinine >120µmol/l). The per-
centage of death at 4-8 weeks follow-up after the inclusion is 4% (9% in
Sweden and 2 in France despite the great similarity between the other charac-
teristics of the population).
 
Conclusions:
 
 Patients in KaRen are “real world” patients with heart failure
and preserved ejection fraction. Age and atrial fibrillation are the two most
determinant characteristics of our population.
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Aim:
 
 The present study investigated possible mechanisms underlying
postischemic remodeling in diabetic hearts. Diabetes (DM) accelerates
postischaemic cardiac remodeling and increases mortality after myocar-
dial infarction. 
 
Methods:
 
 Acute myocardial infarction (AMI) was induced in rats with
type I diabetes (DM) and non diabetic rats (NDM-AMI) while sham operated
animals served as controls (SHAM). All groups were subjected to echocardio-
graphic analysis 2 weeks after infarction. 
